Literature DB >> 22704597

Overcoming multidrug resistance by co-delivery of Mdr-1 and survivin-targeting RNA with reduction-responsible cationic poly(β-amino esters).

Qi Yin1, Jianan Shen, Lingli Chen, Zhiwen Zhang, Wangwen Gu, Yaping Li.   

Abstract

Multidrug resistance (MDR) remains one of the main challenges in the successful chemotherapy of human cancer. RNA interference (RNAi) strategy aiming at only one cause of MDR was widely applied, nevertheless hardly obtained satisfactory tumor-suppressing effect. In this work, a new attempt to package two kinds of RNA with different functions into one vector and reverse MDR against two different mechanisms via RNAi was carried out. A new bioreducible poly (β-amino esters) (PAEs), poly[bis(2-hydroxylethyl)-disulfide-diacrylate-β-tetraethylenepentamine] (PAP) was synthesized by Michael addition reaction. The PAEs/RNA complex nanoparticles (PAEN) were prepared. The experimental results demonstrated that co-delivery of iMdr-1-shRNA and iSurvivin-shRNA could be achieved by a single vector, and interfering two genes simultaneously had a synergistic effect on overcoming MDR. PAEN lowered the IC(50) value of doxorubicin (DOX) in MDR tumor cells to a comparable level to that in the sensitive cell line through down-regulating the expression of P-gp and Survivin, and decreased the tumor volumes in mice xenograft model bearing DOX-resistant human breast cancer when combined with DOX. These results illustrated that PAEN could be applied as potential efficient non-viral RNA carriers for reversing MDR.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22704597     DOI: 10.1016/j.biomaterials.2012.05.039

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  20 in total

1.  Polyamidoamine dendrimers-based nanomedicine for combination therapy with siRNA and chemotherapeutics to overcome multidrug resistance.

Authors:  Jiayi Pan; Livia P Mendes; Momei Yao; Nina Filipczak; Sumanta Garai; Ganesh A Thakur; Can Sarisozen; Vladimir P Torchilin
Journal:  Eur J Pharm Biopharm       Date:  2019-01-08       Impact factor: 5.571

2.  Sequence-dependent combination therapy with doxorubicin and a survivin-specific small interfering RNA nanodrug demonstrates efficacy in models of adenocarcinoma.

Authors:  Subrata K Ghosh; Mehmet V Yigit; Masashi Uchida; Alana W Ross; Natalie Barteneva; Anna Moore; Zdravka Medarova
Journal:  Int J Cancer       Date:  2013-10-15       Impact factor: 7.396

Review 3.  Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances.

Authors:  Nishant S Gandhi; Rakesh K Tekade; Mahavir B Chougule
Journal:  J Control Release       Date:  2014-09-07       Impact factor: 9.776

Review 4.  Recent advances in delivery of drug-nucleic acid combinations for cancer treatment.

Authors:  Jing Li; Yan Wang; Yu Zhu; David Oupický
Journal:  J Control Release       Date:  2013-04-25       Impact factor: 9.776

5.  Effect of siRNA pre-Exposure on Subsequent Response to siRNA Therapy.

Authors:  Hamidreza Montazeri Aliabadi; Parvin Mahdipoor; Cezary Kucharsky; Nicole Chan; Hasan Uludağ
Journal:  Pharm Res       Date:  2015-07-01       Impact factor: 4.200

6.  Folate Receptor Targeted Delivery of siRNA and Paclitaxel to Ovarian Cancer Cells via Folate Conjugated Triblock Copolymer to Overcome TLR4 Driven Chemotherapy Resistance.

Authors:  Steven K Jones; Vincent Lizzio; Olivia M Merkel
Journal:  Biomacromolecules       Date:  2015-12-16       Impact factor: 6.988

Review 7.  Nanomedicine of synergistic drug combinations for cancer therapy - Strategies and perspectives.

Authors:  Rui Xue Zhang; Ho Lun Wong; Hui Yi Xue; June Young Eoh; Xiao Yu Wu
Journal:  J Control Release       Date:  2016-06-08       Impact factor: 9.776

Review 8.  Cancer-Targeting Nanoparticles for Combinatorial Nucleic Acid Delivery.

Authors:  Hannah J Vaughan; Jordan J Green; Stephany Y Tzeng
Journal:  Adv Mater       Date:  2019-06-20       Impact factor: 30.849

9.  A bioreducible linear poly(β-amino ester) for siRNA delivery.

Authors:  Kristen L Kozielski; Stephany Y Tzeng; Jordan J Green
Journal:  Chem Commun (Camb)       Date:  2013-06-11       Impact factor: 6.222

10.  Reducible chimeric polypeptide consisting of octa-D-arginine and tetra-L-histidine peptides as an efficient gene delivery vector.

Authors:  Xiaoyu Wang; Zongguang Tai; Jing Tian; Wei Zhang; Chong Yao; Lijuan Zhang; Yuan Gao; Quangang Zhu; Jing Gao; Shen Gao
Journal:  Int J Nanomedicine       Date:  2015-07-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.